United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News GSK bets on activin signalling with $950m 35Pharma acquisition Discover why GSK plc is acquiring 35Pharma Inc. for $950 million and what HS235 could mean for the future of pulmonary hypertension treatment. byVenkateshFebruary 25, 2026